About this trial
This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).
Eligibility criteria
Qualifiers
Age ≥ 18 years, ≤85 years
The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki
Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.
The patient is willing and able to cooperate with study procedures and required follow up visits
Disqualifiers
Age <18 years and > 85 years.
Single coronary vessel disease.
No left anterior descending lesion.
Patients in cardiogenic shock.
Trial design
Treatments tested in this trial
- PCI with OCT guidance